BPC-157 Dosing Protocol — Sikiric Lab Doses, Routes, and Vial Math
Nearly every "BPC-157 dosing" article you'll find online cites the same number — usually 250 to 500 μg — without sourcing it. The number isn't wrong, but the reasoning behind it is rarely shown. Here's the actual research origin of BPC-157 dosing: the Sikiric Zagreb lab papers, what they used, how they used it, and how researchers translate that to a 5 mg vial reconstituted with bacteriostatic water in 2026.
1. Where the dose numbers come from — the Sikiric lab
Predrag Sikiric's research group at the University of Zagreb has published the great majority of peer-reviewed BPC-157 literature over the past 30 years — over 100 papers on the pentadecapeptide's effects on tendon, ligament, muscle, gastrointestinal tract, vascular, and nervous-system models. If you read a BPC-157 mechanism claim, the citation chain almost always leads back to a Sikiric paper.
Two dose ranges dominate the Sikiric corpus:
- 10 μg/kg — used in most acute injury and inflammation models
- 10 ng/kg — used in some chronic and gut-model studies, showing the unusual phenomenon that a 1000-fold lower dose still produces measurable healing signal
The 10 μg/kg figure is the more commonly cited and replicated. A 250-300 g lab rat at 10 μg/kg receives roughly 2.5-3 μg per administration. The number gets large in human translation because the body-surface-area scaling factor between rat and human is significant.
2. Allometric translation — how 10 μg/kg in a rat becomes 250 μg in a human
The standard interspecies dose translation used by FDA preclinical guidance applies a body-surface-area correction factor. For rat to human, the factor is approximately 6.2 (rat dose mg/kg ÷ 6.2 = human equivalent mg/kg, then × body weight). Applied to BPC-157:
Human equivalent: 10 ÷ 6.2 ≈ 1.6 μg/kg
70 kg human: 1.6 × 70 ≈ 113 μg
That gives the lower end of the most-cited research range (100-500 μg). The upper end of the cited range reflects (1) variation in source papers, (2) some researchers extrapolating from the higher-tolerance findings in the Sikiric ngc/kg arm, and (3) conservative overshoot to account for subcutaneous bioavailability losses. Neither end of this range has been validated in a human RCT.
3. Route — what the Sikiric papers used vs what researchers use today
The Sikiric lab papers used several administration routes depending on the model:
- Intraperitoneal (IP) — most common in rat trauma models; fast distribution.
- Intragastric (oral gavage) — used to demonstrate oral activity in gut and CNS models.
- Drinking water — used in chronic dosing studies.
- Subcutaneous (SC) — used in some musculoskeletal repair models.
Researchers in 2026 typically work with two routes: subcutaneous injection (the one with the most predictable peptide pharmacokinetics) and oral capsule. The deeper BPC-157 research guide covers the mechanism case for each. The pharmacokinetic case favours SC for systemic effects and local injection (intramuscular near the site of interest) for musculoskeletal models.
Oral BPC-157 — the bioavailability question
BPC-157 has a partial sequence-of-origin in gastric juice — its parent protein, BPC ("body protection compound"), was isolated from human gastric juice. This is often cited to argue oral bioavailability. The Sikiric papers showed oral activity in rats. The honest reading: oral activity in rat ≠ characterised oral bioavailability in human. Plasma pharmacokinetic data on oral BPC-157 in humans is not published.
4. 5 mg vial reconstitution math
REVIVE LAB UAE supplies BPC-157 in 5 mg vials — the standard research vial size in the regional market. Reconstitution math for the most-used research doses:
| Bac water added | Concentration | 250 μg dose | 500 μg dose |
|---|---|---|---|
| 1 mL | 5 mg/mL (5000 μg/mL) | 0.05 mL (5 units U-100) | 0.1 mL (10 units) |
| 2 mL | 2.5 mg/mL (2500 μg/mL) | 0.1 mL (10 units) | 0.2 mL (20 units) |
| 5 mL | 1 mg/mL (1000 μg/mL) | 0.25 mL (25 units) | 0.5 mL (50 units) |
Most researchers reach for the 2 mL reconstitution — it gives readable U-100 syringe marks at both common doses without wasting bac water volume. The 5 mL reconstitution suits researchers running very short protocols where the larger fluid volume per dose is acceptable.
5. Stack considerations — BPC-157 + TB-500
The most-discussed BPC-157 stack pairs it with TB-500 (thymosin beta-4 fragment). The mechanism case is reasonable: BPC-157 drives angiogenesis and local healing through nitric oxide and growth factor pathways; TB-500 promotes cell migration and actin sequestration. The two act on different molecular targets in the same broad repair process.
Researchers running stack comparisons should note that controlled trial data for the combination does not exist — the synergy hypothesis is preclinical and anecdotal. See our dedicated BPC-157 vs TB-500 comparison for the full mechanism breakdown.
6. Storage and stability
- Lyophilised vial (unreconstituted): 24+ months stable refrigerated at 2-8 °C. Tolerates room-temperature shipping windows.
- Reconstituted with bac water: 28 days at 2-8 °C is the commonly used window. Some peptide chemistry literature supports longer for shorter peptides like BPC-157 (15 amino acids), but 28 days is the conservative practice.
- Freezer: Possible for the lyophilised form; not recommended for reconstituted vials due to freeze-thaw aggregation.
- Light: Store in original box. Peptides are photosensitive.
7. UAE supply context — why HPLC verification matters
BPC-157 is one of the most commonly counterfeited peptides in the regional grey market. The 15-amino-acid sequence is straightforward to synthesise but easy to under-synthesise — incomplete coupling produces a vial that passes mass-spec by majority signal but fails purity. HPLC verification with a lot-level COA is the primary defence against this. Every BPC-157 vial shipped by REVIVE LAB UAE arrives with an accompanying certificate of analysis tied to the specific lot.
Same-day dispatch from Dubai before 3 PM, 24-hour delivery to Dubai/Abu Dhabi/Sharjah/Ajman, 24-48 hour delivery to Al Ain/RAK/Fujairah. Bacteriostatic water is available in 3 mL vials alongside as bacteriostatic water UAE.
8. The summary
- BPC-157 dosing comes from the Sikiric Zagreb lab papers — 10 μg/kg and 10 ng/kg ranges in rat models.
- Allometric translation to 70 kg human ≈ 100-500 μg per administration. No human RCT validates the specific number.
- Sikiric papers used IP, oral, and SC routes. Researchers today usually use SC; oral bioavailability in humans is uncharacterised.
- 5 mg vial + 2 mL bac water = 2.5 mg/mL stock. 10 units U-100 = 250 μg. 20 units = 500 μg.
- Refrigerated stability after reconstitution: 28 days at 2-8 °C.
- UAE supply: REVIVE LAB UAE 5 mg vials with HPLC certificate, 24-hour delivery across the seven emirates.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Curr Pharm Des. 2011;17(16):1612-32. PubMed
- Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JH. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-80. PubMed
- Sikiric P, Seiwerth S, Rucman R, et al. Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications. Curr Neuropharmacol. 2016;14(8):857-865. PubMed
- Cerovecki T, Bojanic I, Brcic L, et al. Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat. J Orthop Res. 2010;28(9):1155-61. PubMed
- Nair AB, Jacob S. A simple practice guide for dose conversion between animals and human. J Basic Clin Pharm. 2016;7(2):27-31. PubMed